| abstract |
Use of a sulfated non-anticoagulant polysaccharide (PSNA) in the manufacture of a composition to treat a subject in need of improvement in blood coagulation, in which said PSNA shows an anticoagulant activity in a dilute prothrombin time coagulation assay (dPT) or activated thromboplastin time (aPTT) which is not more than one third of the molar anticoagulant activity of the nofractioned heparin, and also in which the PSNA is selected from fucoidan or a fragment thereof, N-acetylheparin (NAH), heparin N-acetyl-des-O-sulfated (NA-de-os-SH), des-N-sulfated heparin (De-NSH), acetylated N-sulfated heparin (N-HSA), pentosan polysulfate (PPS), chondroitin sulfate or dermatan sulfate. |